David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESGR
3126
DELISTED
Enstar Group
ESGR
| $339K | ﹤0.01% |
1,951
-3,461
| -64% | -$601K |
|
3127
Marcus Corp
MCS
$930M
| $339K | ﹤0.01% |
8,476
-8,460
| -50% | -$350K |
|
3128
PC Connection
CNXN
$2B
| $337K | ﹤0.01% |
+9,196
| New | +$331K |
|
|
BID
3129
CALL
DELISTED
Sotheby's
BID
| $336K | ﹤0.01% |
8,900
| – | – |
|
3130
Hooker Furnishings Corp
HOFT
$148M
| $335K | ﹤0.01% |
11,609
-2,086
| -15% | -$61.3K |
|
3131
REX American Resources
REX
$1.37B
| $335K | ﹤0.01% |
24,912
-1,416
| -5% | -$17.9K |
|
|
EGIO
3132
DELISTED
Edgio, Inc. Common Stock
EGIO
| $335K | ﹤0.01% |
2,590
-689
| -21% | -$80K |
|
3133
Community Trust Bancorp
CTBI
$1.39B
| $334K | ﹤0.01% |
8,126
+2,684
| +49% | +$111K |
|
|
WPG
3134
DELISTED
Washington Prime Group Inc.
WPG
| $334K | ﹤0.01% |
6,568
-800
| -11% | -$39.2K |
|
|
HUYA
3135
Huya Inc
HUYA
$491M
| $332K | ﹤0.01% |
+11,816
| New | +$264K |
|
3136
Microchip Technology
MCHP
$39.9B
| $332K | ﹤0.01% |
8,000
-10,284
| -56% | -$426K |
|
3137
Royal Gold
RGLD
$22.7B
| $332K | ﹤0.01% |
3,652
-62,183
| -94% | -$5.43M |
|
3138
Rogers Corp
ROG
$2.23B
| $332K | ﹤0.01% |
2,087
-995
| -32% | -$134K |
|
3139
Rayonier Advanced Materials
RYAM
$582M
| $332K | ﹤0.01% |
24,487
+470
| +2% | +$6.37K |
|
|
DAY
3140
DELISTED
Dayforce
DAY
| $332K | ﹤0.01% |
+6,463
| New | +$286K |
|
|
NLSN
3141
DELISTED
Nielsen Holdings plc
NLSN
| $332K | ﹤0.01% |
14,006
-76,047
| -84% | -$1.97M |
|
|
BRSL
3142
Brightstar Lottery PLC
BRSL
$2.12B
| $331K | ﹤0.01% |
25,458
-86,383
| -77% | -$1.33M |
|
3143
Sierra Bancorp
BSRR
$512M
| $330K | ﹤0.01% |
13,578
-1,046
| -7% | -$27.1K |
|
3144
CALL
Itaú Unibanco
ITUB
$84.4B
| $330K | ﹤0.01% |
51,537
| – | – |
|
3145
Veritone
VERI
$87.4M
| $329K | ﹤0.01% |
+63,301
| New | +$353K |
|
3146
CALL
CACI
CACI
$13.5B
| $328K | ﹤0.01% |
+1,800
| New | +$307K |
|
|
COR
3147
DELISTED
Coresite Realty Corporation
COR
| $327K | ﹤0.01% |
+3,054
| New | +$303K |
|
3148
PUT
Abercrombie & Fitch
ANF
$4.84B
| $326K | ﹤0.01% |
11,900
-41,500
| -78% | -$931K |
|
|
SRNE
3149
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $324K | ﹤0.01% |
68,126
-825,874
| -92% | -$2.17M |
|
|
CARB
3150
DELISTED
Carbonite Inc
CARB
| $323K | ﹤0.01% |
13,025
-20,179
| -61% | -$519K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.